Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/21/17 → 12/31/21 |
Funding
- CTI Clinical Trial and Consulting Services: $810,764.00
16-GBM-12-BE (BXQ-350-AA) Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Glioblastoma Multiforme
- Villano, PhD, John (PI)